Latest News
Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies
24 September 2021 - - US-based synthetic biology and genomics company Twist Bioscience Corp's (NASDAQ: TWST) internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, inclu...
SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
24 September 2021 - - An independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3...
Reven Completes the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients
24 September 2021 - - US-based biotechnology and pharmaceutical company Reven Holdings, Inc has completed Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Reven's lead anti-sepsis drug candidate RJX in hospitalized high-risk C...
Pfizer's Dolsten Named to Agilent Board of Directors
24 September 2021 - - Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to US-based Agilent Technologies, Inc's (NYSE: A) board of directors, the company said.
Long-Term Crysvita Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia, a Rare Genetic Metabolic Bone Disease
24 September 2021 - - New data has been published highlighting the sustained benefits of treatment with Crysvita (burosumab) in adults with X-linked hypophosphataemia, a rare genetic metabolic bone disease, Japanese pharmaceutical company Kyowa Kirin...